Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

PURPOSE: To compare the efficacy and safety of ranibizumab and bevacizumab intravitreal injections to treat neovascular age-related macular degeneration (nAMD). DESIGN: Multicenter, noninferiority factorial trial with equal allocation to groups. The noninferiority limit was 3.5 letters. This trial i...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän:	Chakravarthy, U, Harding, S, Rogers, C, Downes, S, Lotery, A, Wordsworth, S, Reeves, B
Materialtyp:	Journal article
Språk:	English
Publicerad:	2012

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial av Chakravarthy, U, Harding, S, Rogers, C, Downes, S, Lotery, A, Wordsworth, S, Reeves, B

Publicerad 2012

Journal article

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial av Chakravarthy, U, Harding, S, Rogers, C, Downes, S, Lotery, A, Wordsworth, S, Reeves, B

Liknande verk